ARTICLE | Clinical News
Metastron: Phase II
February 12, 2001 8:00 AM UTC
In a U.S. Phase II trial of Metastron in combination with doxorubicin in 72 patients with prostate cancer with bone metastases, patients who received one dose of Metastron had a median survival time o...